Search

Displaying results 1941 - 1950 of 10000 in total
  1. Indication

    Degenerative Joint Disease

    go.drugbank.com/conditions/DBCOND0039319
    Drugs: Methylprednisolone
    Synonyms: O/A
  2. Indication

    Sezary Syndrome

    go.drugbank.com/conditions/DBCOND0001518
    Drugs: Doxorubicin · Isotretinoin · Pentostatin
    Synonyms: Cutaneous T-cell lymphoma, no ICD-O subtype
  3. Indication

    Squamous Cell Carcinoma (SCC)

    go.drugbank.com/conditions/DBCOND0043488
    Drugs: Bleomycin
    Synonyms: Squamous cell carcinoma, no ICD-O subtype
  4. Indication

    Splinter

    go.drugbank.com/conditions/DBCOND0015551
    Drugs: Ichthammol
    Synonyms: Splinter in skin (disorder)
  5. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: COTELLIC® (COBIMETINIB) 20 MG TABLETAS RECUBIERTAS
  6. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. … Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  7. Target

    Cytoplasmic tyrosine-protein kinase BMX

    go.drugbank.com/bio_entities/BE0009416
    TargetHumans

    May also play a role in the growth and differentiation of hematopoietic cells; as well as in signal transduction in endocardial and arterial endothelial cells … Plays a critical role in TNF-induced angiogenesis, and implicated in the signaling of TEK and FLT1 receptors, 2 important receptor families essential for angiogenesis.

    Synonyms: Bone marrow tyrosine kinase gene in chromosome X protein
  8. Drug

    Zotepine

    go.drugbank.com/drugs/DB09225
    ApprovedWithdrawn

    In 1993, it was classified as inactive drug substance (Status I, Type II) and in 1995 the FDA studied the manufacturing procedures of Zotepine tablets in Germany, but the status remained inactive. … [L1082] When the analysis of antipsychotics was retaken in 2016 by the FDA, zotepine did not reach the threshold effect to be further studied.[L1313].

    Categories: Dopamine D2 Receptor Antagonists, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: ZOLEPTIL © 50 MG TABLETAS RECUBIERTAS.
  9. Drug

    Nepidermin

    go.drugbank.com/drugs/DB14145
    Investigational

    Mixtures: EASYDEW DW EGF Derma Oneshot AmpouleCategories: EGF Family of Proteins
  10. Drug

    Cinacalcet

    go.drugbank.com/drugs/DB01012
    ApprovedInvestigational

    Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. … It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine, N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine